Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Praxis Precision MedicinesPRAX -0.85%38 3-Year EBITDA Growth Rate is 40.80% as of Jun. 2026, which is at its 10-year median of 40.80. GuruFocus rates PRAX with a GF Score™ of 38/100 and a GF Value™ of $16.67 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,130 Biotechnology companies, Praxis Precision Medicines ranks better than 78.94% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 40.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 36.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Praxis Precision Medicines was 43.10% per year. The lowest was -30.80% per year. And the median was 40.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Praxis Precision Medicines 3-Year EBITDA Growth Rate Related Terms
PRAX vs KYMR, SYRE, CRNX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Praxis Precision Medicines's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Praxis Precision Medicines 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Praxis Precision Medicines's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 40.80% mean?
Praxis Precision Medicines (PRAX) has a 3-Year EBITDA Growth Rate of 40.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Praxis Precision Medicines and its competitors. This is near median its historical median of 40.80. According to the industry distribution chart, Praxis Precision Medicines ranks #238 out of 1130 companies in the Biotechnology industry, placing it in the top 21.1%.
Is Praxis Precision Medicines' 3-Year EBITDA Growth Rate too high?
Praxis Precision Medicines' current 3-Year EBITDA Growth Rate of 40.80% is near median its 10-year median of 40.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Praxis Precision Medicines' value of 40.80% is 174.7% above this industry median. Based on the distribution chart, Praxis Precision Medicines ranks #238 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Praxis Precision Medicines has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Praxis Precision Medicines' 3-Year EBITDA Growth Rate compare to KYMR and SYRE?
According to the Biotechnology industry distribution chart, Praxis Precision Medicines ranks #238 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Praxis Precision Medicines in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Praxis Precision Medicines' value of 40.80% is 174.7% above this benchmark. While the company's 10-year median is 40.80 vs. the industry median of 14.85, Praxis Precision Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Praxis Precision Medicines's current 3-Year EBITDA Growth Rate of 40.80% is 174.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Praxis Precision Medicines and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Praxis Precision Medicines's current 3-Year EBITDA Growth Rate is 40.80%, which is near median its own 10-year median of 40.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praxis Precision Medicines stock overvalued right now?
Based on GuruFocus' analysis, Praxis Precision Medicines (PRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $16.67, compared to a current price of $365.23 — trading 2090.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 40.80%, which is near median its 10-year median of 40.80 and 174.7% above the Biotechnology industry median of 14.85. Praxis Precision Medicines' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Praxis Precision Medicines (PRAX), the current 3-Year EBITDA Growth Rate is 40.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Praxis Precision Medicines (PRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued.
The current stock price of $365.23 is trading 2090.9% above its estimated GF Value™ of $16.67.
GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.
Key valuation signals for PRAX:
3-Year EBITDA Growth Rate: 40.80% (near median its 10-year median of 40.80)
GF Value™: $16.67 vs. price of $365.23 (2090.9% above fair value)
Industry Position: 174.7% above the Biotechnology median (#238 of 1130)
No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score
Get the complete analysis for PRAX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRAX has been successfully added to your 
